Africa to Receive Revolutionary Twice-Yearly HIV Prevention Shot
Lenacapavir, a biannual injectable HIV prevention drug, is rolling out to low-income countries in Africa through a collaboration between Gilead, the Global Fund, and generics makers. Proven nearly 100% effective in trials, its success depends on overcoming logistical challenges and securing funding, and could transform HIV prevention across the continent.